# Interleukin 12 (IL-12) (MEDI1191)

**Last program update: October 29, 2020**

<table>
<thead>
<tr>
<th>Modality</th>
<th>ID #</th>
<th>Program Indication</th>
<th>Preclinical development</th>
<th>Phase 1</th>
<th>Phase 2</th>
<th>Phase 3 and commercial</th>
<th>Moderna rights</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intratumoral immunology</td>
<td>mRNA-2416</td>
<td>OX40L Solid tumors/lymphoma</td>
<td>Solid tumors/lymphoma</td>
<td>Ovarian</td>
<td></td>
<td>Worldwide</td>
<td></td>
</tr>
<tr>
<td></td>
<td>mRNA-2752</td>
<td>OX40L/IL-23/IL-36γ (triplet) Solid tumors/lymphoma</td>
<td>Solid tumors/lymphoma</td>
<td></td>
<td></td>
<td>Worldwide</td>
<td></td>
</tr>
<tr>
<td></td>
<td>MEDI1191</td>
<td>IL-12 Solid tumors</td>
<td>Solid tumors/lymphoma</td>
<td></td>
<td></td>
<td>50-50 U.S. profit sharing: AZ to pay royalties on ex-U.S. sales</td>
<td></td>
</tr>
</tbody>
</table>

**Phase 1 study of MEDI1191 ongoing; study run by AstraZeneca**
mRNA-encoding IL-12 (MEDI1191)
mRNA-encoded cytokine to activate tumor microenvironment
IL-12 (MEDI1191) overview

Powerful immunomodulatory cytokine well-suited for local delivery

- IL-12: potent immune modulator typically associated with a type 1 immune response and production of interferon-gamma
- Clinical development of systemically administered recombinant IL-12 has been hampered by systemic toxicity
- We have demonstrated well-tolerated intratumoral doses of IL-12 mRNA induce complete responses in multiple mouse models of cancer, exert abscopal effects on distal tumors, and yield protective immunity
- Clear rationale for the combination of IL-12 and PD-1/PD-L1 blockade

Modern concept: Intratumorally-administered mRNA encoding IL-12 to activate tumor microenvironment
Forward-looking statements

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended including, but not limited to, statements concerning potential development candidate applications, development candidate activities, preclinical and clinical studies, regulatory submissions and approvals, risk management and estimates and forward-looking projections with respect to Moderna or its anticipated future performance or events. In some cases, forward-looking statements can be identified by terminology such as “may,” “should,” “expects,” “intends,” “plans,” “aims,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “continue,” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. The forward-looking statements in this presentation are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties and other factors, many of which are beyond Moderna’s control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties and other factors include, among others: preclinical and clinical development is lengthy and uncertain, especially for a new category of medicines such as mRNA, and therefore Moderna’s preclinical programs or development candidates may be delayed, terminated, or may never advance to or in the clinic; no mRNA drug has been approved in this new potential category of medicines, and may never be approved; mRNA drug development has substantial clinical development and regulatory risks due to the novel and unprecedented nature of this new category of medicines; and those described in Moderna’s most recent Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) and in subsequent filings made by Moderna with SEC, which are available on the SEC’s website at www.sec.gov. Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements in this presentation in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna’s current expectations and speak only as of the date hereof.